Metabolic resuscitation using early administration of ascorbic acid, thiamine and hydrocortisone in perioperative management of surgical patients with septic shock: A Randomized Controlled trial

AIIMS NEW DELHI0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. Perioperative septic shock: peritonitis due to hollow viscus perforation, ruptured solid organ abscess, pyoperitoneum, intestinal obstruction.
•2. Controlled source of infection: Post-intervention (surgical or non-surgical) control of source of infection
•3. 18 to 70 years, both gender
•4. Ready to participate in the study

•1. Age < 18 years and > 70 years
•2. Refusal to consent and DNR orders (patient or patients family do not consent for the resuscitation and study)
•3. Septic shock for > 24 hours
•4. Failure to administer intervention drugs within 6 hours of presentation of septic shock
•5. Proven active COVID-19 infection, HIV infection, known immunodeficiency diseases
•6. Allergy to either of the intervention drugs (allergy to ascorbic acid or thiamine or hydrocortisone)
•7. Uncontrollable source of infection e.g., Unresectable dead bowel,
•8. Recurrent, unresectable or metastatic cancer
•9. Patient on antifungal infection for systemic fungal infection
•10. Imminent death or Inevitable deaths: metastatic cancer or haematological malignancy, more than four failed organs at entry (or multiorgan dysfunction syndrome), APACHE II score > 30 at presentation, granulocytopenia leucocyte count < 500cells/ml and/or thrombocytopenia < 30000 cells/ml)
•11. Alternate diagnosis causing shock e.g., myocardial infarction and severe congestive cardiac failure (NYHA class IV), pulmonary embolism, Child Pugh class C liver disease, patients on immunosuppressantÃ¢â?¬•s, chemotherapy / radiotherapy within 30 days prior to sepsis, haemorrhagic shock or GCS-3.
•12. Pregnancy or breastfeeding
•13. G6PD deficiency
•14. Patients already on hydrocortisone, ascorbic acid and thiamine for reasons other than septic shock

发起方

AIIMS NEW DELHI